Abstract
Currently available surrogate markers of osteoporosis including areal bone mineral density (aBMD) measured by dual energy absorptiometry (DXA), bone turnover markers (BTMs), and fracture risk assessment tool (FRAX®) are limited for the use as targets, because those values are not directly reflecting bone strength. Because directly measuring the strength of any bone in a living human subject is not feasible, the combination of finite element analysis (FEA) and clinical computed tomography (CT) is an alternative and powerful technique for noninvasive assessment of whole bone strength. While there are several limitations including the radiation exposure, FEA has the potential to improve clinical assessment of osteoporosis. In this chapter, methodology and recent advances of FEA in this field including treatment efficacy assessment and fracture risk assessment are presented.
This work was supported in part by JSPS KAKENHI (Grant No. 24592269).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Keaveny TM (2010) Biomechanical computed tomography-noninvasive bone strength analysis using clinical computed tomography scans. Ann N Y Acad Sci 1192:57–65. doi:10.1111/j.1749-6632.2009.05348.x
Kanis JA, McCloskey E, Branco J, Brandi ML, Dennison E, Devogelaer JP, Ferrari S, Kaufman JM, Papapoulos S, Reginster JY, Rizzoli R (2014) Goal-directed treatment of osteoporosis in Europe. Osteoporos Int 25(11):2533–2543. doi:10.1007/s00198-014-2787-1
Jacques RM, Boonen S, Cosman F, Reid IR, Bauer DC, Black DM, Eastell R (2012) Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27(8):1627–1634. doi:10.1002/jbmr.1644
Zysset PK, Dall’ara E, Varga P, Pahr DH (2013) Finite element analysis for prediction of bone strength. Bonekey Rep 2:386. doi:10.1038/bonekey.2013.120
Keaveny TM, Donley DW, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA (2007) Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 22(1):149–157. doi:10.1359/jbmr.061011
Mawatari T, Miura H, Hamai S, Shuto T, Nakashima Y, Okazaki K, Kinukawa N, Sakai S, Hoffmann PF, Iwamoto Y, Keaveny TM (2008) Vertebral strength changes in rheumatoid arthritis patients treated with alendronate, as assessed by finite element analysis of clinical computed tomography scans: a prospective randomized clinical trial. Arthritis Rheum 58(11):3340–3349. doi:10.1002/art.23988
Crawford RP, Cann CE, Keaveny TM (2003) Finite element models predict in vitro vertebral body compressive strength better than quantitative computed tomography. Bone 33(4):744–750. doi:10.1016/s8756-3282(03)00210-2
Imai K, Ohnishi I, Bessho M, Nakamura K (2006) Nonlinear finite element model predicts vertebral bone strength and fracture site. Spine 31(16):1789–1794
Graeff C, Chevalier Y, Charlebois M, Varga P, Pahr D, Nickelsen TN, Morlock MM, Gluer CC, Zysset PK (2009) Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS study. J Bone Miner Res 24(10):1672–1680. doi:10.1359/jbmr.090416
Dall’Ara E, Pahr D, Varga P, Kainberger F, Zysset P (2012) QCT-based finite element models predict human vertebral strength in vitro significantly better than simulated DEXA. Osteoporos Int 23(2):563–572. doi:10.1007/s00198-011-1568-3
Imai K, Ohnishi I, Yamamoto S, Nakamura K (2009) Assessment of vertebral fracture risk and therapeutic effects of alendronate in postmenopausal women using a quantitative computed tomography-based nonlinear finite element method. Osteoporos Int 20:801–810. doi:10.1007/s00198-008-0750-8
Lewiecki EM, Keaveny TM, Kopperdahl DL, Genant HK, Engelke K, Fuerst T, Kivitz A, Davies RY, Fitzpatrick LA (2009) Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 94(1):171–180. doi:10.1210/jc.2008-1807
Gluer CC, Marin F, Ringe JD, Hawkins F, Moricke R, Papaioannu N, Farahmand P, Minisola S, Martinez G, Nolla JM, Niedhart C, Guanabens N, Nuti R, Martin-Mola E, Thomasius F, Kapetanos G, Pena J, Graeff C, Petto H, Sanz B, Reisinger A, Zysset PK (2013) Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res 28(6):1355–1368. doi:10.1002/jbmr.1870
Cosman F, Keaveny TM, Kopperdahl D, Wermers RA, Wan X, Krohn KD, Krege JH (2013) Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. J Bone Miner Res 28(6):1328–1336. doi:10.1002/jbmr.1853
Keaveny TM, McClung MR, Genant HK, Zanchetta JR, Kendler D, Brown JP, Goemaere S, Recknor C, Brandi ML, Eastell R, Kopperdahl DL, Engelke K, Fuerst T, Radcliffe HS, Libanati C (2014) Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab. J Bone Miner Res 29(1):158–165. doi:10.1002/jbmr.2024
Brixen K, Chapurlat R, Cheung AM, Keaveny TM, Fuerst T, Engelke K, Recker R, Dardzinski B, Verbruggen N, Ather S, Rosenberg E, de Papp AE (2013) Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. J Clin Endocrinol Metab 98(2):571–580. doi:10.1210/jc.2012-2972
Orwoll ES, Shapiro J, Veith S, Wang Y, Lapidus J, Vanek C, Reeder JL, Keaveny TM, Lee DC, Mullins MA, Nagamani SC, Lee B (2014) Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Invest 124(2):491–498. doi:10.1172/JCI71101
Keaveny T, Myers S, Chiang A, Alam J, Robins D, Krege J, Sipos A, Mitlak B, Benson C (2013) Effects of blosozumab on estimated spine and hip strength in postmenopausal women with low bone mineral density: finite element analysis of a phase-II dosing study. J Bone Miner Res 28(Suppl 1). Available at http://www.asbmr.org/education/AbstractDetail?aid=7214d65b-b1c1-4ad1-bd87-23206e3630cb. Accessed 30 June 2015
Melton LJ 3rd, Riggs BL, Keaveny TM, Achenbach SJ, Hoffmann PF, Camp JJ, Rouleau PA, Bouxsein ML, Amin S, Atkinson EJ, Robb RA, Khosla S (2007) Structural determinants of vertebral fracture risk. J Bone Miner Res 22(12):1885–1892. doi:10.1359/jbmr.070728
Wang X, Sanyal A, Cawthon PM, Palermo L, Jekir M, Christensen J, Ensrud KE, Cummings SR, Orwoll E, Black DM, Osteoporotic Fractures in Men Research G, Keaveny TM (2012) Prediction of new clinical vertebral fractures in elderly men using finite element analysis of CT scans. J Bone Miner Res 27(4):808–816. doi:10.1002/jbmr.1539
Kopperdahl DL, Aspelund T, Hoffmann PF, Sigurdsson S, Siggeirsdottir K, Harris TB, Gudnason V, Keaveny TM (2014) Assessment of incident spine and hip fractures in women and men using finite element analysis of CT scans. J Bone Miner Res 29(3):570–580. doi:10.1002/jbmr.2069
Saito M, Marumo K (2010) Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes melitus. Osteoporos Int 21(2):195–214. doi:10.1007/s00198-009-1066-z
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Japan
About this chapter
Cite this chapter
Mawatari, T., Ikemura, S., Iwamoto, Y. (2016). Vertebral Strength Changes as Assessed by Finite Element Analysis. In: Shimada, Y., Miyakoshi, N. (eds) Osteoporosis in Orthopedics. Springer, Tokyo. https://doi.org/10.1007/978-4-431-55778-4_5
Download citation
DOI: https://doi.org/10.1007/978-4-431-55778-4_5
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-55777-7
Online ISBN: 978-4-431-55778-4
eBook Packages: MedicineMedicine (R0)